Signia Therapeutics
French tech company | Builders Republic
About
Biotech repurposing existing antiviral compounds to treat acute respiratory infections — combining known drug molecules with proprietary formulation or delivery approaches to accelerate clinical development.
Key facts
- Status
- Morte
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2017
- City
- LYON
- Region
- Auvergne-Rhône-Alpes
- Tracked rounds
- 1
- Amount raised
- 1.3 M€ raised since 2020
Funding rounds
- Seed — 2021
Investors
- Néovacs
Notes
Liquidation judiciaire ouverte le 26/10/2023 (cessation des paiements au 01/10/2023), clôture pour insuffisance d'actifs le 22/05/2024 ; société inactive.